Benzinga  Sep 11  Comment 
Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced that it has entered into a Memorandum of Understanding for an exclusive distribution and reseller agreement with Contém 1G, one of the leading cosmetics companies in...
Biomass Magazine  Aug 7  Comment 
Amyris Inc. has released second quarter financial results, reporting GAAP revenues of $7.8 million, down from $9.3 million during the same quarter of 2014. The company reported a net loss attributable to common stockholders of $47.1 million.
TheStreet.com  Jul 16  Comment 
NEW YORK (TheStreet) -- Shares of Amyris were gaining 22.74% to $2.21 on heavy trading volume Thursday after the industrial bioscience company announced a new multi-year collaboration agreement with a global food ingredients supplier. The new...
Biomass Magazine  Jul 2  Comment 
Amyris Inc. has announced an update and clarification with respect to media reports regarding its inactive manufacturing joint venture with Usina Sao Martinho, SMA Industria Quimica S.A, or SMA., noting its Brotas facility is exceeding targets.
Benzinga  Jul 1  Comment 
Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced an update and clarification with respect to media reports regarding its inactive manufacturing joint venture with Usina São Martinho, SMA Indústria Química S.A, or...
Biomass Magazine  Jun 30  Comment 
Amyris Inc. has announced that it has agreed on key business terms with Total Energies Nouvelles Activites USA for restructuring its fuels joint venture to open the way for proceeding with commercialization of its jet fuel technology.
Biomass Magazine  Jun 29  Comment 
Amyris Inc. has announced the successful completion of a diesel demonstration program with Volkswagen of America Inc. that was designed to test the commercial readiness of Amyris renewable diesel and its ability to enhance VW's diesel technology.


Amyris Biotechnologies (NASDAQ:AMRS) creates, sells, and distributes renewable products that replace chemicals and fuels made from petroleum. Amyris genetically modifies yeast cells to ferment feedstocks into a series of different target molecules. The company then sells these target molecules to replace additives or fuels which are made from petroleum. The company originally focused on using sugar cane stalks and turned them into farnesene which is key additive in detergents, cosmetics, and transportable fuels among other things. Amyris has continued to diversify both the inputs it can take and the output molecules it can produce. Amyris has pushed to make its products competitive, both in price and effectiveness of replacement, even if they are renewable.[1]

Amyris currently does not have any commercial level efforts in place. It has only established a test facility next to its laboratories in California. The company hopes to expand to commercial distribution levels during 2011 by establishing contracts with sugar cane mills in Brazil. The company has agreed through a letter of intent with a large Brazilian manufacturer to establish a joint venture facility which would turn 10% of their sugar cane into farnesene.[2] The company has also entered into commercialization agreements with large chemical and cosmetic companies such as Procter & Gamble Company (PG).[3]

The company's initial public offering of stock filed on the NASDAQ and went public on the 27 of September 2010. It priced at $16, which was well below the initial price range of $18-$20. The company raised $85M by offering 5.3M shares. The lead underwriter of the deal were J P Morgan Chase (JPM), Morgan Stanley (MS), and Goldman Sachs Group (GS).[4]

Despite not producing at commercial levels, the company has achieved a net revenue for 2009 of $65M. However, due to the high Research & Development costs associated to its developmental stage, it incurred a net loss of $64M.[5]


  1. AMRS S-1/A 2010 "Our Company" pg 1
  2. AMRS S-1/A 2010 "Commercial Production" pg 2
  3. AMRS S-1/A 2010 "Commercialization and Distribution" pg 2
  4. Renaissance Capital - IPO "Amyris Biotechnologies prices IPO at $16, below the proposed range" 28 Sept 2010
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki